摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-氟-1H-苯并咪唑-2-甲醇 | 39811-07-9

中文名称
6-氟-1H-苯并咪唑-2-甲醇
中文别名
(5-氟-1H-苯并咪唑-2-基)甲醇
英文名称
(5-fluoro-1H-benzimidazole-2-yl)methanol
英文别名
(5-fluoro-1H-benzo[d]imidazol-2-yl)methanol;5-Fluor-2-hydroxymethyl-benzimidazol;(6-fluoro-1H-benzimidazol-2-yl)methanol
6-氟-1H-苯并咪唑-2-甲醇化学式
CAS
39811-07-9
化学式
C8H7FN2O
mdl
MFCD09261475
分子量
166.155
InChiKey
WFGVOSSDGZOYNE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    416.1±25.0 °C(Predicted)
  • 密度:
    1.468±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    48.9
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:ed8fbbca475a0eced7983f8e66487549
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : (5-Fluoro-1H-Benzimidazol-2-Yl)Methanol
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 166,16 g/mol
No components need to be disclosed according to the applicable regulations.

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
No special environmental precautions required.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
No special environmental precautions required.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-氟-1H-苯并咪唑-2-甲醇potassium permanganate 作用下, 以 丙酮 为溶剂, 以37%的产率得到6-氟-苯并咪唑-2-甲酸
    参考文献:
    名称:
    选定的苯并咪唑衍生物作为潜在抗菌剂的合成与评价。
    摘要:
    合成了53个苯并咪唑衍生物的文库,它们在1、2和5位具有取代基,并针对一系列与医学相关的细菌和真菌参考菌株进行了筛选。SAR分析最有前景的结果表明,化合物的抗菌活性取决于与双环杂环相连的取代基。特别是,某些化合物对两种耐甲氧西林的金黄色葡萄球菌(MRSA)菌株表现出抗菌活性,其最低抑制浓度(MIC)与广泛使用的环丙沙星药物相当。这些化合物具有一些共同特征。三个具有5-卤素取代基;两个是(S)-2-乙胺苯并咪唑的衍生物;其他是一种2-(氯甲基)-1H-苯并[d]咪唑和(1H-苯并[d]咪唑-2-基)甲硫醇的衍生物。抗真菌筛选的结果也非常有趣:23种化合物对选定的真菌菌株显示出有效的杀真菌活性。它们的MIC值显示出比两性霉素B相同或更高的效力。5-卤代苯并咪唑衍生物被认为是有前途的广谱抗微生物候选物,值得进一步研究以用于潜在的治疗应用。
    DOI:
    10.3390/molecules200815206
  • 作为产物:
    描述:
    羟基乙酸4-氟-1,2-苯二胺盐酸 作用下, 以 为溶剂, 反应 8.0h, 以70%的产率得到6-氟-1H-苯并咪唑-2-甲醇
    参考文献:
    名称:
    选定的苯并咪唑衍生物作为潜在抗菌剂的合成与评价。
    摘要:
    合成了53个苯并咪唑衍生物的文库,它们在1、2和5位具有取代基,并针对一系列与医学相关的细菌和真菌参考菌株进行了筛选。SAR分析最有前景的结果表明,化合物的抗菌活性取决于与双环杂环相连的取代基。特别是,某些化合物对两种耐甲氧西林的金黄色葡萄球菌(MRSA)菌株表现出抗菌活性,其最低抑制浓度(MIC)与广泛使用的环丙沙星药物相当。这些化合物具有一些共同特征。三个具有5-卤素取代基;两个是(S)-2-乙胺苯并咪唑的衍生物;其他是一种2-(氯甲基)-1H-苯并[d]咪唑和(1H-苯并[d]咪唑-2-基)甲硫醇的衍生物。抗真菌筛选的结果也非常有趣:23种化合物对选定的真菌菌株显示出有效的杀真菌活性。它们的MIC值显示出比两性霉素B相同或更高的效力。5-卤代苯并咪唑衍生物被认为是有前途的广谱抗微生物候选物,值得进一步研究以用于潜在的治疗应用。
    DOI:
    10.3390/molecules200815206
点击查看最新优质反应信息

文献信息

  • BOIMPYs: Rapid Access to a Family of Red-Emissive Fluorophores and NIR Dyes
    作者:Lukas J. Patalag、Peter G. Jones、Daniel B. Werz
    DOI:10.1002/anie.201606883
    日期:2016.10.10
    bridging ligand at the meso position enables the binding of two BF2 units to provide sufficient rigidity and enhanced electron‐withdrawing strength. Absorption and emission events thus take place in the red (λ≈600 nm); the fluorescence quantum yields can reach unity (0.96) and show little dependence on solvent polarity. The synthetic route was shortened to two steps starting from commercially available
    报道了衍生自BODIPY核心的基本的,高度荧光的且易于获得的支架。通过使用苯并咪唑作为介孔桥联配体,可以使两个BF 2单元结合,从而提供足够的刚度和增强的吸电子强度。因此,吸收和发射事件以红色(λ≈600 nm); 荧光量子产率可以达到1(0.96),并且几乎不依赖于溶剂极性。从市售前体开始,将合成路线缩短为两个步骤,而制备则是模块化的,并且可以耐受各种吡咯和苯并咪唑部分。丙炔基取代的氟化物,各种卤化以及Knoevenagel型缩合反应被用来扩展这些新的光稳定荧光团的多功能性,我们将其称为BOIMPYs。
  • Sustainable Synthesis of 2‐Hydroxymethylbenzimidazoles using D‐Fructose as a C <sub>2</sub> Synthon
    作者:Dineshkumar Raja、Abigail Philips、Devikala Sundaramurthy、Gopal Chandru Senadi
    DOI:10.1002/asia.202100972
    日期:2021.11.15
    carbohydrate has been identified as an environmentally benign C2 synthon in the preparation of synthetically useful 2-hydroxymethylbenzimidazole derivatives by coupling with 1,2-phenylenediamines. The pivotal features of this method include metal-free conditions, short time, good functional group tolerance, gram scale feasibility and the synthesis of benzimidazole fused 1,4-oxazine.
    D-果糖是一种生物质衍生的碳水化合物,在通过与 1,2-苯二胺偶联制备合成有用的 2-羟甲基苯并咪唑衍生物时,已将其鉴定为环境无害的 C 2合成子。该方法的关键特征包括无金属条件、时间短、官能团耐受性好、克级可行性和苯并咪唑稠合 1,4-恶嗪的合成。
  • COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS
    申请人:ACADEMIA SINICA
    公开号:US20150168415A1
    公开(公告)日:2015-06-18
    Provided is an isotope-labelled compound having a general formula IIa′, S-Y′-BIM, wherein S is a sugar moiety, Y′ is an isotope-containing sensor moiety and BIM is a benzimidazole. The compound may be used as an agent for saccharide analysis by magnetic resonance spectroscopy (NMR). A new glycan sequencing method and a glycoprotein synthesis method by using these compounds are also provided.
    提供的是具有一般公式IIa′,S-Y′-BIM的同位素标记化合物,其中S是糖基团,Y′是含同位素的传感器基团,BIM是苯并咪唑。该化合物可用作磁共振波谱(NMR)中的糖分析试剂。还提供了一种利用这些化合物的新糖基序列方法和糖蛋白合成方法。
  • Octahydropyrrolo[3,4-C]pyrrole derivatives
    申请人:Lane Alice Louise Charlotte
    公开号:US20060111416A1
    公开(公告)日:2006-05-25
    The present invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives of formula (I): and to processes for the preparation thereof, compositions containing the same and the uses thereof.
    本发明涉及式(I)的八氢吡咯并[3,4-c]吡咯衍生物,以及其制备方法、含有该衍生物的组合物和用途。
  • [EN] INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A<br/>[FR] INHIBITEURS CIBLANT LA GRIPPE A PHARMACORÉSISTANTE
    申请人:UNIV PENNSYLVANIA
    公开号:WO2013086131A1
    公开(公告)日:2013-06-13
    Provided are compounds according to formula (la) or (lb) as described herein, that are capable of modulating the activity of influenza viruses (e.g., influenza A virus), for example, via interaction with the M2 transmembrane protein, and other similar viroporins. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds according to according to formulas (la') or (lb), as described herein.
    根据本文描述的公式(la)或(lb),提供了一些化合物,这些化合物能够调节流感病毒(例如流感A病毒)的活性,例如通过与M2跨膜蛋白以及其他类似的病毒孔蛋白相互作用。还提供了一种治疗流感A感染疾病状态或感染的方法,包括通过给予包含根据本文描述的公式(la')或(lb)的一个或多个化合物的组合物进行治疗。
查看更多